Amgen and Teva Pharmaceuticals Industries have been granted permission for an expedited appeal in an antitrust case related to Amgen’s Sensipar, a calcium reducer, after a lower court decision.
According to a memorandum by Judge Colm F. Connolly in the US District Court for the District of Delaware, pharmaceutical companies have the right to appeal a decision if he finds that he does not have the authority to allow an interlocutory appeal of a previous judge’s ruling.
Related: Warren Sends Letter To FTC Over Amgen & Indivior Deals
There is “substantial ground for difference of opinion” about whether a judge can certify for interlocutory appeal another judge’s order in the same case, Connolly said.
Featured News
FCC Set to Reinstate Net Neutrality Rules Today
Apr 25, 2024 by
CPI
Chamber of Commerce Sues to Overturn FTC Non-Compete Ban
Apr 24, 2024 by
CPI
FTC Chief Warns of Healthcare Price Fixing Risks Amid Tech Advancements
Apr 24, 2024 by
CPI
Amazon’s Investment in Anthropic Faces Antitrust Scrutiny
Apr 24, 2024 by
CPI
Italian Antitrust Authority Fines Amazon €10 Million for Unfair Trade Practices
Apr 24, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI